TLDRs; BYD’s profit rose 14% to US$2.1 billion in H1 2025, supported by strong global EV demand. Revenue jumped 23% year-on-year as total deliveries hit 2.2 million vehicles, up 33% from last year. China’s EV market faces a looming shakeout, with only 15 brands expected to survive consolidation by 2030. BYD overtook Tesla in European [...] The post BYD Profit Jumps 14% as Global EV Demand Fuels Growth appeared first on CoinCentral.TLDRs; BYD’s profit rose 14% to US$2.1 billion in H1 2025, supported by strong global EV demand. Revenue jumped 23% year-on-year as total deliveries hit 2.2 million vehicles, up 33% from last year. China’s EV market faces a looming shakeout, with only 15 brands expected to survive consolidation by 2030. BYD overtook Tesla in European [...] The post BYD Profit Jumps 14% as Global EV Demand Fuels Growth appeared first on CoinCentral.

BYD Profit Jumps 14% as Global EV Demand Fuels Growth

TLDRs;

  • BYD’s profit rose 14% to US$2.1 billion in H1 2025, supported by strong global EV demand.
  • Revenue jumped 23% year-on-year as total deliveries hit 2.2 million vehicles, up 33% from last year.
  • China’s EV market faces a looming shakeout, with only 15 brands expected to survive consolidation by 2030.
  • BYD overtook Tesla in European EV registrations in April 2025, with sales soaring 359% despite tariff concerns.

BYD, China’s largest electric vehicle (EV) maker, posted a 14% rise in net profit for the first half of 2025, underlining the company’s resilience amid an increasingly competitive global EV market.

The Shenzhen-based automaker reported earnings of 15.5 billion yuan (US$2.1 billion), driven by robust international sales and growing demand for fully electric cars.

Revenue climbed 23% year-on-year to 371.3 billion yuan (US$51.9 billion), with total deliveries hitting 2.2 million vehicles, an increase of 33% compared to the same period last year. However, the results also revealed a slowdown in plug-in hybrid sales, which dipped in the second quarter, even as demand for battery-only EVs accelerated.

EV Price Wars Heat Up in China

While BYD’s performance highlighted its operational strength, industry analysts warn the second half of the year will be more challenging. China’s domestic EV market is undergoing an intense period of consolidation, with relentless price cuts squeezing profit margins across the sector.

According to consulting firm AlixPartners, only 15 of the 129 EV brands currently operating in China are expected to survive by 2030, with these players capturing 75% of the market. This looming shakeout has prompted regulators in Beijing to push automakers to scale back discounting practices, fearing that unchecked price wars could destabilize even financially sound companies.

BYD’s ability to maintain profitability despite the competitive environment underscores the advantage of scale and efficiency. With its vertically integrated supply chain, from batteries to vehicle assembly, the automaker is better positioned than most rivals to withstand shrinking margins while continuing to expand market share.

European Expansion Strengthens Momentum

Beyond China, BYD is achieving notable breakthroughs in international markets. Its European expansion strategy has begun to pay off, with the company surpassing Tesla in EV registrations across Europe for the first time in April 2025.

Sales in the region surged 359% year-on-year, marking a turning point for Chinese automakers seeking to establish themselves in premium Western markets.

The milestone came as Tesla’s European sales fell nearly 49% in the same period, highlighting a direct competitive shift rather than just a broad industry upswing. BYD also began shipping EVs to Europe from its Thai manufacturing base, signaling a strategy of diversified production to support global growth.

This progress was achieved despite ongoing debates over tariffs on Chinese EVs. Analysts note that BYD’s value-for-money offering has proven strong enough to overcome trade barriers and appeal to European consumers. With sales expanding beyond early footholds in Norway and the Netherlands into broader markets, the company is building a foundation for sustained growth outside its home turf.

Challenges Ahead for BYD

Despite the strong half-year results, challenges remain for the automaker. Analysts caution that intensified competition, stricter regulatory scrutiny on pricing, and inventory balancing efforts could limit profit growth in the remainder of 2025.

Still, BYD’s ability to combine profit growth with rapid international expansion demonstrates its leading position in the global EV landscape. As industry consolidation accelerates and smaller competitors struggle to survive, the company’s scale, efficiency, and expanding global presence could make it one of the long-term winners in the EV transition.

 

The post BYD Profit Jumps 14% as Global EV Demand Fuels Growth appeared first on CoinCentral.

Market Opportunity
Oasis Logo
Oasis Price(ROSE)
$0.01411
$0.01411$0.01411
+2.84%
USD
Oasis (ROSE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26